PAR 7.02% 26.5¢ paradigm biopharmaceuticals limited..

Benchmarks for Phase II Rare Disease Partnering Transactions...

  1. 2,126 Posts.
    lightbulb Created with Sketch. 569
    Benchmarks for Phase II Rare Disease Partnering Transactions (2016 – 2023) (n=47)

    Low Median High
    Upfront Cash (US$ M) 1 18 900
    Milestones (US$ M) 3 200 1,700
    Royalties 9% 15% 40%
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.